Clinical Trial

Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma

Study acronym: HEME-18
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a phase II study where patients will undergo isatuximab and lenalidomide maintenance if they are MRD-positive after Autologous Stem Cell Transplant (ASCT)
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2022-04-19; most recent amendment 2026-02-19.
Status change: Not Yet Recruiting → Recruiting 2022-11-15
Trial Details
NCT Number NCT05344833
Lead Sponsor University of Illinois at Chicago
Collaborators: Huntsman Cancer Institute
Conditions Multiple Myeloma
Enrollment 50 participants
Start Date 2023-01-05
Primary Completion 2030-12 (estimated)
Study Completion 2030-12 (estimated)
Updated on ClinicalTrials.gov 2026-02-23